Investing.com -- Moody’s Ratings has uplifted the rating of Royalty Pharma plc’s senior unsecured notes from Baa3 to Baa2. The outlook for the company has also been revised, shifting from positive to ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter ...

How CDMOs are reshaping pharmaceutical partnerships through friendshoring, risk-sharing economics, and specialized development capabilities.

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

BofA raised the firm’s price target on Royalty Pharma (RPRX) to $42 from $41 and keeps a Buy rating on the shares. The firm, in its preview of ...

Ligand Pharmaceuticals offers biotech exposure with reduced risk through its royalty platform. Discover why its valuation now ...

Fintel reports that on April 17, 2025, Benchmark initiated coverage of XOMA Royalty (NasdaqGM:XOMA) with a Buy recommendation ...

In an ever-expanding field, firms are racing to attract new talent – just as a major shortage of stockbrokers looms. 2025 has been a rocky year so far for equity investors, but how you respond ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Royalty Pharma plc (NASDAQ:RPRX), a pharmaceutical company with a robust market capitalization of $13.52 billion and strong financial health metrics according to InvestingPro, has entered into an ...

Royalty Pharma plc (NASDAQ:RPRX), a pharmaceutical company with a robust market capitalization of $13.52 billion and strong financial health metrics according to InvestingPro, has entered into an ...